Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Bobcat339

Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription[1].

Product Specifications

CAS Number

[2280037-51-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA Methyltransferase; TET Protein

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bobcat339.html

Purity

99.44

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=NC(N(C2=CC=CC(C3=CC=CC=C3)=C2)C=C1Cl)=O

Molecular Formula

C16H12ClN3O

Molecular Weight

297.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Chua GNL, et, al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31; 10 (2) : 180-185.|[2]Weirath NA, et al. Small Molecule Inhibitors of TET Dioxygenases: Bobcat339 Activity Is Mediated by Contaminating Copper (II) . ACS Med Chem Lett. 2022 Apr 21;13 (5) :792-798.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

TET1; TET2

Citation 01

Aquaculture. 2023: 739234.|Br J Pharmacol. 2024 Oct;181 (20) :3886-3907.|Brain Sci. 2023 Apr 10;13 (4) :644.|EMBO Mol Med. 2025 Oct;17 (10) :2809-2826.|Eur J Pharmacol. 2024 Aug 23:176931.|J Exp Clin Cancer Res. 2025 Jul 15;44 (1) :206.|Research Square Print. 2023 Mar 14.|Research Square Print. November 29th, 2022.|Bioelectrochemistry. 2023 Aug:152:108433.|Cancers (Basel) . 2022 Jun 16;14 (12) :2983.|Cell Death Dis. 2024 Jun 1;15 (6) :387.|Clin Epigenetics. 2024 Oct 2;16 (1) :136.|Clin Sci. 2023 Aug 31;137 (16) :1265-1283.|Environ Sci Technol. 2021 Mar 2;55 (5) :3144-3155.|J Clin Invest. 2023 Oct 16;133 (20) :e170173.|J Pharm Biomed Anal. 2021 Sep 5:203:114228.|Mol Pain. 2022 Apr;18:17448069221143671.|Nat Metab. 2025 Jul;7 (7) :1344-1357.|Neuropharmacology. 2024 Feb 15:244:109799.|Sci Total Environ. 2024 Apr 1:919:170905.|Theranostics. 2021 Jun 11;11 (16) :7640-7657.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Absolut Mag NHS-Activated Magnetic Particles Conjugation Kit, 150 nm
DAGF-012-01 10 mg

Absolut Mag NHS-Activated Magnetic Particles Conjugation Kit, 150 nm

Ask
View Details
Absolut Mag NHS-Activated Magnetic Particles Conjugation Kit, 150 nm
DAGF-012-02 1 mg

Absolut Mag NHS-Activated Magnetic Particles Conjugation Kit, 150 nm

Ask
View Details
Biotinylated Anti-TIGIT antibody (EN0178) ; Rabbit mAb
E33E100178B 100 µL

Biotinylated Anti-TIGIT antibody (EN0178) ; Rabbit mAb

Ask
View Details
V6 Anti-Human SELP (Crizanlizumab)
B23150501-01 1 mg

V6 Anti-Human SELP (Crizanlizumab)

Ask
View Details
V6 Anti-Human SELP (Crizanlizumab)
B23150501-02 5 mg

V6 Anti-Human SELP (Crizanlizumab)

Ask
View Details
V6 Anti-Human SELP (Crizanlizumab)
B23150501-03 25 mg

V6 Anti-Human SELP (Crizanlizumab)

Ask
View Details